Spinal and Bulbar Muscular Atrophy Treatment Market, Global Outlook and Forecast 2022-2028
SBMA, mainly manifested as systemic muscle atrophy, paralysis and systemic muscle bundle tremor, patients with systemic muscle weakness, especially the weakness of the two lower limbs to walk, tongue muscle atrophy is usually one of the main symptoms.
This report contains market size and forecasts of Spinal and Bulbar Muscular Atrophy Treatment in Global, including the following market information:
Global Spinal and Bulbar Muscular Atrophy Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Spinal and Bulbar Muscular Atrophy Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
5?-Reductase Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Spinal and Bulbar Muscular Atrophy Treatment include AbbVie, Pfizer, GlaxoSmithKline, Johnson & Johnson, Century Pharmaceuticals, Astellas Pharma, Sanofi and Boehringer Ingelheim International, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spinal and Bulbar Muscular Atrophy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spinal and Bulbar Muscular Atrophy Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Spinal and Bulbar Muscular Atrophy Treatment Market Segment Percentages, by Type, 2021 (%)
Global Spinal and Bulbar Muscular Atrophy Treatment Market Segment Percentages, by Application, 2021 (%)
Global Spinal and Bulbar Muscular Atrophy Treatment Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Spinal and Bulbar Muscular Atrophy Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Spinal and Bulbar Muscular Atrophy Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
This report contains market size and forecasts of Spinal and Bulbar Muscular Atrophy Treatment in Global, including the following market information:
Global Spinal and Bulbar Muscular Atrophy Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Spinal and Bulbar Muscular Atrophy Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
5?-Reductase Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Spinal and Bulbar Muscular Atrophy Treatment include AbbVie, Pfizer, GlaxoSmithKline, Johnson & Johnson, Century Pharmaceuticals, Astellas Pharma, Sanofi and Boehringer Ingelheim International, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Spinal and Bulbar Muscular Atrophy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Spinal and Bulbar Muscular Atrophy Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Spinal and Bulbar Muscular Atrophy Treatment Market Segment Percentages, by Type, 2021 (%)
- 5?-Reductase Inhibitors
- Gonadotropin-releasing Hormone Agonists
Global Spinal and Bulbar Muscular Atrophy Treatment Market Segment Percentages, by Application, 2021 (%)
- Hospitals
- Orthopedic Clinics
- Ambulatory Surgical Centers
Global Spinal and Bulbar Muscular Atrophy Treatment Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Spinal and Bulbar Muscular Atrophy Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Spinal and Bulbar Muscular Atrophy Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AbbVie
- Pfizer
- GlaxoSmithKline
- Johnson & Johnson
- Century Pharmaceuticals
- Astellas Pharma
- Sanofi
- Boehringer Ingelheim International
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Spinal and Bulbar Muscular Atrophy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Spinal and Bulbar Muscular Atrophy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL SPINAL AND BULBAR MUSCULAR ATROPHY TREATMENT OVERALL MARKET SIZE
2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size: 2021 VS 2028
2.2 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Spinal and Bulbar Muscular Atrophy Treatment Players in Global Market
3.2 Top Global Spinal and Bulbar Muscular Atrophy Treatment Companies Ranked by Revenue
3.3 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Companies
3.4 Top 3 and Top 5 Spinal and Bulbar Muscular Atrophy Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Spinal and Bulbar Muscular Atrophy Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Spinal and Bulbar Muscular Atrophy Treatment Players in Global Market
3.6.1 List of Global Tier 1 Spinal and Bulbar Muscular Atrophy Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Spinal and Bulbar Muscular Atrophy Treatment Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Markets, 2021 & 2028
4.1.2 5?-Reductase Inhibitors
4.1.3 Gonadotropin-releasing Hormone Agonists
4.2 By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue & Forecasts
4.2.1 By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2022
4.2.2 By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2023-2028
4.2.3 By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Orthopedic Clinics
5.1.4 Ambulatory Surgical Centers
5.2 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue & Forecasts
5.2.1 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2022
5.2.2 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2023-2028
5.2.3 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2021 & 2028
6.2 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue & Forecasts
6.2.1 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2022
6.2.2 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2023-2028
6.2.3 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.3.2 US Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.3.3 Canada Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.3.4 Mexico Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.4.2 Germany Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.3 France Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.4 U.K. Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.5 Italy Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.6 Russia Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.8 Benelux Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.5.2 China Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5.3 Japan Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5.4 South Korea Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5.6 India Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.6.2 Brazil Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.6.3 Argentina Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.7.2 Turkey Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.7.3 Israel Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.7.5 UAE Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 AbbVie
7.1.1 AbbVie Corporate Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.1.4 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.1.5 AbbVie Key News
7.2 Pfizer
7.2.1 Pfizer Corporate Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.2.4 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.2.5 Pfizer Key News
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Corporate Summary
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.3.4 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.3.5 GlaxoSmithKline Key News
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Corporate Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.4.4 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.4.5 Johnson & Johnson Key News
7.5 Century Pharmaceuticals
7.5.1 Century Pharmaceuticals Corporate Summary
7.5.2 Century Pharmaceuticals Business Overview
7.5.3 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.5.4 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.5.5 Century Pharmaceuticals Key News
7.6 Astellas Pharma
7.6.1 Astellas Pharma Corporate Summary
7.6.2 Astellas Pharma Business Overview
7.6.3 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.6.4 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.6.5 Astellas Pharma Key News
7.7 Sanofi
7.7.1 Sanofi Corporate Summary
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.7.4 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.7.5 Sanofi Key News
7.8 Boehringer Ingelheim International
7.8.1 Boehringer Ingelheim International Corporate Summary
7.8.2 Boehringer Ingelheim International Business Overview
7.8.3 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.8.4 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.8.5 Boehringer Ingelheim International Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Spinal and Bulbar Muscular Atrophy Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Spinal and Bulbar Muscular Atrophy Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL SPINAL AND BULBAR MUSCULAR ATROPHY TREATMENT OVERALL MARKET SIZE
2.1 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size: 2021 VS 2028
2.2 Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Spinal and Bulbar Muscular Atrophy Treatment Players in Global Market
3.2 Top Global Spinal and Bulbar Muscular Atrophy Treatment Companies Ranked by Revenue
3.3 Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Companies
3.4 Top 3 and Top 5 Spinal and Bulbar Muscular Atrophy Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Spinal and Bulbar Muscular Atrophy Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Spinal and Bulbar Muscular Atrophy Treatment Players in Global Market
3.6.1 List of Global Tier 1 Spinal and Bulbar Muscular Atrophy Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Spinal and Bulbar Muscular Atrophy Treatment Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Spinal and Bulbar Muscular Atrophy Treatment Market Size Markets, 2021 & 2028
4.1.2 5?-Reductase Inhibitors
4.1.3 Gonadotropin-releasing Hormone Agonists
4.2 By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue & Forecasts
4.2.1 By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2022
4.2.2 By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2023-2028
4.2.3 By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Orthopedic Clinics
5.1.4 Ambulatory Surgical Centers
5.2 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue & Forecasts
5.2.1 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2022
5.2.2 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2023-2028
5.2.3 By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2021 & 2028
6.2 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue & Forecasts
6.2.1 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2022
6.2.2 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2023-2028
6.2.3 By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.3.2 US Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.3.3 Canada Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.3.4 Mexico Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.4.2 Germany Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.3 France Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.4 U.K. Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.5 Italy Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.6 Russia Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.4.8 Benelux Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.5.2 China Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5.3 Japan Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5.4 South Korea Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.5.6 India Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.6.2 Brazil Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.6.3 Argentina Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028
6.7.2 Turkey Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.7.3 Israel Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
6.7.5 UAE Spinal and Bulbar Muscular Atrophy Treatment Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 AbbVie
7.1.1 AbbVie Corporate Summary
7.1.2 AbbVie Business Overview
7.1.3 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.1.4 AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.1.5 AbbVie Key News
7.2 Pfizer
7.2.1 Pfizer Corporate Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.2.4 Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.2.5 Pfizer Key News
7.3 GlaxoSmithKline
7.3.1 GlaxoSmithKline Corporate Summary
7.3.2 GlaxoSmithKline Business Overview
7.3.3 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.3.4 GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.3.5 GlaxoSmithKline Key News
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Corporate Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.4.4 Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.4.5 Johnson & Johnson Key News
7.5 Century Pharmaceuticals
7.5.1 Century Pharmaceuticals Corporate Summary
7.5.2 Century Pharmaceuticals Business Overview
7.5.3 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.5.4 Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.5.5 Century Pharmaceuticals Key News
7.6 Astellas Pharma
7.6.1 Astellas Pharma Corporate Summary
7.6.2 Astellas Pharma Business Overview
7.6.3 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.6.4 Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.6.5 Astellas Pharma Key News
7.7 Sanofi
7.7.1 Sanofi Corporate Summary
7.7.2 Sanofi Business Overview
7.7.3 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.7.4 Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.7.5 Sanofi Key News
7.8 Boehringer Ingelheim International
7.8.1 Boehringer Ingelheim International Corporate Summary
7.8.2 Boehringer Ingelheim International Business Overview
7.8.3 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Major Product Offerings
7.8.4 Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global Market (2017-2022)
7.8.5 Boehringer Ingelheim International Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Spinal and Bulbar Muscular Atrophy Treatment Market Opportunities & Trends in Global Market
Table 2. Spinal and Bulbar Muscular Atrophy Treatment Market Drivers in Global Market
Table 3. Spinal and Bulbar Muscular Atrophy Treatment Market Restraints in Global Market
Table 4. Key Players of Spinal and Bulbar Muscular Atrophy Treatment in Global Market
Table 5. Top Spinal and Bulbar Muscular Atrophy Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Spinal and Bulbar Muscular Atrophy Treatment Product Type
Table 9. List of Global Tier 1 Spinal and Bulbar Muscular Atrophy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Spinal and Bulbar Muscular Atrophy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Corporate Summary
Table 31. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 32. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Pfizer Corporate Summary
Table 34. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 35. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 36. GlaxoSmithKline Corporate Summary
Table 37. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 38. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Johnson & Johnson Corporate Summary
Table 40. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 41. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Century Pharmaceuticals Corporate Summary
Table 43. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 44. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Astellas Pharma Corporate Summary
Table 46. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 47. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Sanofi Corporate Summary
Table 49. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 50. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Boehringer Ingelheim International Corporate Summary
Table 52. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 53. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 1. Spinal and Bulbar Muscular Atrophy Treatment Market Opportunities & Trends in Global Market
Table 2. Spinal and Bulbar Muscular Atrophy Treatment Market Drivers in Global Market
Table 3. Spinal and Bulbar Muscular Atrophy Treatment Market Restraints in Global Market
Table 4. Key Players of Spinal and Bulbar Muscular Atrophy Treatment in Global Market
Table 5. Top Spinal and Bulbar Muscular Atrophy Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Spinal and Bulbar Muscular Atrophy Treatment Product Type
Table 9. List of Global Tier 1 Spinal and Bulbar Muscular Atrophy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Spinal and Bulbar Muscular Atrophy Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Spinal and Bulbar Muscular Atrophy Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2023-2028
Table 30. AbbVie Corporate Summary
Table 31. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 32. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Pfizer Corporate Summary
Table 34. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 35. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 36. GlaxoSmithKline Corporate Summary
Table 37. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 38. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Johnson & Johnson Corporate Summary
Table 40. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 41. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 42. Century Pharmaceuticals Corporate Summary
Table 43. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 44. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Astellas Pharma Corporate Summary
Table 46. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 47. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Sanofi Corporate Summary
Table 49. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 50. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Boehringer Ingelheim International Corporate Summary
Table 52. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Product Offerings
Table 53. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Spinal and Bulbar Muscular Atrophy Treatment Segment by Type in 2021
Figure 2. Spinal and Bulbar Muscular Atrophy Treatment Segment by Application in 2021
Figure 3. Global Spinal and Bulbar Muscular Atrophy Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Spinal and Bulbar Muscular Atrophy Treatment Revenue in 2021
Figure 8. By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 12. US Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 24. China Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Spinal and Bulbar Muscular Atrophy Treatment Segment by Type in 2021
Figure 2. Spinal and Bulbar Muscular Atrophy Treatment Segment by Application in 2021
Figure 3. Global Spinal and Bulbar Muscular Atrophy Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Spinal and Bulbar Muscular Atrophy Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Spinal and Bulbar Muscular Atrophy Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Spinal and Bulbar Muscular Atrophy Treatment Revenue in 2021
Figure 8. By Type - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 12. US Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 24. China Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Spinal and Bulbar Muscular Atrophy Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Spinal and Bulbar Muscular Atrophy Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. AbbVie Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Pfizer Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. GlaxoSmithKline Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Johnson & Johnson Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Century Pharmaceuticals Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Astellas Pharma Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Sanofi Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Boehringer Ingelheim International Spinal and Bulbar Muscular Atrophy Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
